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Abstract
Background: X-linked ichthyosis is a dermatological condition caused by deficiency for the enzyme steroid
sulfatase. Previously, X-linked ichthyosis/steroid sulfatase deficiency has been associated with developmental and
neurological phenotypes. Here, we show for the first time, that X-linked ichthyosis may be comorbid with an
additional psychiatric phenotype (psychosis).
Case presentation: We report the case of an 11-year-old Saudi Arabian boy with X-linked ichthyosis associated
with psychosis, mental retardation, autism spectrum disorder, inattentive attention deficit hyperactivity disorder, and
epilepsy. Genetic analysis revealed a 1.68 Mb deletion encompassing STS in 95% of cells while biochemical analysis
revealed correspondingly low steroid sulfatase activity consistent with a diagnosis of X-linked ichthyosis. The
psychotic symptoms could be reasonably well controlled by administration of an atypical antipsychotic.
Conclusions: This report describes a case of comorbid X-linked ichthyosis and psychosis (most closely corresponding
to early-onset schizophrenia) for the first time, and suggests that deficiency for steroid sulfatase and contiguous genes
may increase vulnerability to psychosis as well as other psychological disorders.
Keywords: Attention deficit hyperactivity disorder, Autism spectrum disorder, Case report, Epilepsy, Psychosis,
Steroid sulfatase, X-linked ichthyosis
Background
The ichthyoses are a group of dermatological conditions
characterized by dry scaly skin; most of these disorders
are hereditary, but examples of sporadic or acquired
forms have been reported. Inherited ichthyoses are usu-
ally apparent during the first year of life, often at birth,
and continue to affect a person throughout life [1]. In
1965, Wells and Kerr first recognized X-linked ichthy-
osis (XLI) in 81 affected males [2]. Approximately 90%
of cases of XLI are caused by deletions within, or
encompassing, the steroid sulfatase (STS) gene on
chromosome Xp22.31, with ~ 10% caused by point
mutations within the STS gene [3]; deletions may be
“typical” (encompassing STS and a small number of
adjacent genes), or “atypical” (encompassing many con-
tiguous genes). XLI may occur solely as a skin disorder
or may be associated with other physical findings such
as corneal opacities (up to 50% of cases), cryptorchidism
(20% of cases), chondrodysplasia punctata, and nephrotic
syndrome [4–6]. Deletions encompassing STS have been
reported to be associated with multiple behavioral, cog-
nitive, and neurological phenotypes notably: mental re-
tardation, developmental conditions including autism
spectrum disorders (ASDs), attention deficit hyper-
activity disorder (ADHD), and seizures [7]. In the first
systematic behavioral study of boys with XLI, Kent et al.
showed high rates of ADHD (particularly inattentive
ADHD) and autism-related conditions; the latter were
seen when the deletions were large and included the
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neuroligin 4 gene (NLGN4X) [8]. Consistent with these
data, genetic variants within STS are associated with in-
attentive symptoms in children with ADHD [9, 10] while
mice lacking the Sts gene exhibit behavioral phenotypes
associated with developmental disorders including in-
attention, hyperactivity, elevated emotional reactivity,
behavioral perseveration, and aggression [11–13]. STS is
expressed in brain regions associated with attention, im-
pulsivity, and the integration of, and response to, sensory
information [10]. XLI rarely interferes with the activities
of daily living and individuals with mild forms may not
require treatment [4]. The skin condition can be
managed relatively effectively, but some patients may
experience a significantly reduced quality of life due to
self-consciousness and social embarrassment or due to co-
morbid behavioral, cognitive, or neurological conditions;
such patients may require lifelong treatment [14, 15].
Case presentation
A summary of the case presentation and management is
provided in Table 1. An 11-year-old Saudi Arabian boy,
in Grade Three of primary school, initially presented
with a year-long history of epileptic fits in the form of
abnormal jerky movement of upper limbs accompanied
by fixed eye gaze. The episodes typically lasted for a few
seconds each, with up to 15 episodes per day, and were
often preceded by episodes of unexplained crying.
The boy was born at 28 weeks’ gestation by spontan-
eous vaginal delivery after an uneventful and uncompli-
cated pregnancy. He had a low birth weight of 1.5 kg
(below the 5th centile). During pregnancy, his mother
took no medication apart from folic acid supplementa-
tion during the first trimester. Following delivery, he was
kept in the intermediate care unit for 3 months until he
gained sufficient weight. At birth, he was diagnosed with
congenital ichthyosis although the subtype was not de-
fined; from early childhood, his parents were advised by
the dermatologist of the importance of daily bathing and
regular application of emollient creams containing urea.
His language and gross motor milestones were delayed;
he had poor social interaction with others and restricted
play. There was a family history of developmental
disorders (speech and language problems and learning
disability), and the boy’s 13-year-old sister exhibited mild
mental retardation. There was no family history of
ichthyosis, or psychotic or mood disorder.
The boy’s parents reported that his academic perform-
ance was poor, that he had a learning disability and that
he required substantial support in school. His parents
also reported that, coincidentally with the epileptic fits,
he started exhibiting behavioral changes, becoming so-
cially withdrawn, unresponsive, and preoccupied. He
also became restless and wandered aimlessly, shouted
and made odd noises, began to believe that others were
watching him, and was seen talking to himself and
laughing without any reason. His parents initially sought
help from traditional healers who provided him with
herbal medicine for a short period of time (honey and
herbal oil). After no improvement in the boy’s symp-
toms, his parents arranged for him to be seen by a local
psychiatrist and a neurologist. According to the boy’s
father, initial blood test results (which included full
Table 1 Timeline of case presentation
Timeline Symptoms and treatment
Birth Born at 28 weeks’ gestation: low
birth weight with undefined
congenital ichthyosis
Early childhood Language and gross motor
milestones delayed; poor social
interaction and restricted play;
learning disability and poor
academic performance
Initial presentation at 11 years Year-long history of epileptic fits and
coincident behavioral abnormalities;
initial treatment with herbal
remedies before consultation with
physicians at local hospital.
Presented to local hospital with
acute symptoms of agitation and
unresponsiveness; began to believe
that others were watching him. Was
seen talking to himself and laughing
without reason.
Electroencephalograph abnormalities
detected and carbamazepine and
olanzapine treatment initiated, but
ineffective due to poor patient
adherence
One month later Referred as emergency admission to
tertiary hospital with acute psychotic
episode (with decline in daily
functioning and double incontinence);
microcephaly and ichthyosis noted.
Three-week treatment with lorazepam
initiated
Three weeks later Referral to dermatology, genetics,
neurology, and child psychiatry
clinics. Genetic and biochemical
confirmation of steroid sulfatase
deficiency (X-linked ichthyosis), and
detection of autosomal regions of




pulse therapy and immunoglobulin
regime initiated to treat suspected
encephalitis, but ineffective in
treating cognitive symptoms after 5
days. Olanzapine treatment initiated
which brought psychiatric symptoms
under control after 2 weeks
Follow-up No psychotic symptoms evident;
patient maintained on olanzapine for
1 year following hospital discharge.
Diagnoses of autism spectrum
disorder and attention deficit
hyperactivity disorder made
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blood counts, liver function test, urea and electrolytes,
and thyroid function test) were normal; however, an
electroencephalograph (EEG) showed epileptiform dis-
charges. Carbamazepine (100 mg per day) and olanza-
pine treatment (5 mg, twice per day) were instigated to
treat the boy’s EEG abnormalities and his disturbed be-
havior respectively; carbamazepine was considered to be
the optimum treatment to alleviate his brief episodes of
staring with unresponsiveness which were suggestive of
complex partial seizures. However, his adherence to the
treatment regime was poor: he did not take his medica-
tion as prescribed and had no regular follow-up. Hence
there was minimal improvement in his condition.
One month after his initial presentation to local
doctors, the boy was urgently referred and admitted to a
tertiary hospital. He was extremely aggressive and
attempted to bite his parents and siblings; he was also
verbally abusive, highly vocal (screaming), and restless.
His sleep pattern was extremely disturbed; he remained
awake for the majority of the 3 days prior to admission.
He became doubly incontinent. On examination, the ad-
mitting doctor documented microcephaly and dry skin
with scales over his body (which the patient was peeling
off and eating); there was no erythema. His vital signs
were stable, and there were no neurological signs apart
from eye twitches. He was shouting and uncooperative,
and was looking around as if responding to visual stim-
uli. He was also talking to himself and mumbling. He
was disoriented with regard to time and place, and dem-
onstrated poor general knowledge, even in a simple
color-naming task. He was restless and aggressive, re-
quired sedation, and lorazepam (0.5 mg twice per day)
was administered orally from the day of admission. He
showed immediate improvements in his sleep pattern
and became less agitated and restless. However, he per-
sisted in talking to himself and continued to be suspi-
cious and paranoid. His presentation and symptoms
were considered to best resemble the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition
(DSM-5.0) diagnostic criteria for early-onset schizophre-
nia [16]. Therefore, he continued to be treated with
lorazepam for a 2-week period, with treatment tapering
off within the third week.
He was subsequently referred to several subspecialties
including dermatology, genetics, neurology, and child
psychiatry. During the hospital course, a number of
physiological and metabolic measures were taken
(Table 2).
Most of our patient’s results were within the normal
range, although relatively low levels of hemoglobin and
relatively high values for erythrocyte sedimentation rate
(ESR) and pyruvate were noted.
On the basis of family history and skin appearance,
dermatologists suspected XLI and continued prescribing
emollient creams containing urea. Chromosomal G-
banding and fluorescence in situ hybridization (FISH) ana-
lysis on peripheral blood and fibroblast cultures revealed
an interstitial deletion within Xp22.31 on 95% of the ex-
amined cells with a low level of mosaicism (5% of cells
with normal karyotype). Consistent with the FISH ana-
lysis, STS activity in fibroblasts was low at 3.5 nmol/hour/
protein (normal range, 5 to 32 nmol/hour/protein). The
boy’s genomic deoxyribonucleic acid was assayed on a
combined comparative genomic hybridization (CGH) and
single nucleotide polymorphism (SNP) array in an attempt
to specify a genetic basis for his clinical presentation. The
array CGH study confirmed a 1.68 Mb deletion within the
cytogenetic band Xp22.31 (hg 19: 6,456,036-8,139,238)
that contains the STS gene in addition to VCX3A, PUDP,
VCX, and PNPLA4 genes, and two microRNAs (MIR4767
and MIR651) [17]. His mother was tested for mutation
carrier status, but his siblings were not genetically tested.
Eight regions of homozygosity spanning ~ 111Mb in total
were detected within our patient across multiple auto-
somes (Table 3). Subsequent targeted exome sequencing
of these homozygosity blocks using next generation se-
quencing and capillary Sanger sequencing did not reveal
any pathological, likely pathological, or other sequence
change of possible clinical relevance in the coding regions
of the genes within these regions.
Radiological and neurological investigations using
computed tomography (CT) revealed a structurally nor-
mal brain. A CT venogram showed no evidence of cere-
bral venous thrombosis. Magnetic resonance imaging
(MRI) indicated mild periventricular leukomalacia, pos-
sibly related to our patient’s premature birth. Two EEGs
were performed; the first one performed initially during
his stay in the hospital and the second one was 2
months after his discharge. The first EEG showed mild
slowing of the background with no evidence of any epi-
leptiform discharges; the second EEG showed mild, but
improved, slowing with no evidence of epileptiform dis-
charge. An autoimmune etiology was entertained by the
neurologist; this was partially on the basis of a clear
cerebrospinal fluid (CSF) and acute behavioral symp-
toms; thus, a methylprednisolone pulse therapy regime
(50 mg/kg) to treat suspected encephalitis was initiated
for a period of 5 days, in addition to intravenously
administered immunoglobulin over another 5 days.
These therapies did not improve our patient’s symptoms
of disorientation, cognitive dysfunction, and psychosis.
He showed some improvement in symptoms with a sub-
sequent management regime of 5 mg olanzapine twice
per day, but he demonstrated poor compliance with this.
The psychiatry team opted to continue him on this drug
but at higher doses (the dose was increased from 10 mg
to 20 mg per day gradually over a 2-week period) to
control his psychotic symptoms, as per prescribing
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guidelines [18]; olanzapine is a second-generation anti-
psychotic which has been shown to have robust clinical
benefits for treating early-onset schizophrenia [19]. With
this revised treatment regime, his psychiatric symptoms
were brought under control, and eventually he was dis-
charged with follow-up appointments in ophthalmology
(for bilateral iris mammillation), psychiatric, pediatric
neurology, and dermatology clinics.
The follow-up by the psychiatric clinic revealed no
psychotic symptoms as indexed by the mental state
examination; he was maintained on olanzapine 15 mg
per day for almost 1 year after he was discharged from
our hospital. Neuropsychological testing revealed a non-
verbal intelligence quotient (IQ) of 57 with Test of Non-
verbal Intelligence, Second Edition (TONI-2), consistent
with a mild intellectual disability, and an ASD on the
basis of the Autism Diagnostic Observation Schedule
Table 2 Levels of serum and cerebrospinal fluid metabolites in





WBC 6.1 × 109 4.0–12.0 × 109/L
Hemoglobin 12.9 113–150 g/L
Urea 4 2.5–6 mmol/L
Sodium 137 138–145 mmol/L
Potassium 4 3.4–4.7 mmol/L
Chloride 103 95–110 mmol/L
CO2 22 20–28 mmol/L
Creatinine 46 27–62 mmol/L
Albumin 39 38–54 g/L
Calcium 2.2 2.2–2.7 mmol/L
Phosphorus 1.7 1.05–1.85 mmol/L
Magnesium 0.81 0.7–0.85 mmol/L
Total bilirubin 18 3.4–20.5 umol/L
AST 26 5–34 U/L
ALT 15 5–55 U/L
TP 66 60–80 g/L
ESR 20 0–15 mm/hour
C-reactive protein <3.5 <3.5
GTP 45 12–64 U/L
Ammonia 61 18–72 umol/L
TSH 3.01 0.35–4.94 mIU/L
FT4 10.7 9–19 pmol/L
TSH antibodies Negative Negative
FT4 antibodies Negative Negative
TSH hormone receptor
antibodies
0.5 (Negative) <1.8 IU/L
CK 128 30–200 U/L
Copper 22.9 11.78–22.77 umol/L
Pyruvate 0.315 0.08–0.16 mmol/L
Vitamin D 146.9 62.6–228.0 pmol/L
Vitamin A 687 300–700 ug/L
Ceruloplasmin 0.36 0.20–0.60 g/L
Carbamazepine level 27 17–42 umol/L
Homocysteine level 10 ≤15.0 umol/L
Lead level <0.18 ≤1.22 umol/L
Mycoplasma IgM 3.6 <10 index is negative
Mycoplasma IgG <10.0 <10.0 AU/ml negative
EBV <10 <20 U/ML negative
Cytomegalovirus <5.0 <12.0 U/ml negative
Antistreptolysin O titer 286 >200 IU
Brucella antibodies <1:160 <1:160 is negative
C3 1.45 0.80–1.70 g/L
Table 2 Levels of serum and cerebrospinal fluid metabolites in




C4 0.09 0.14–0.44 g/L
Antinuclear antibodies 0.50 <1.5 index is negative
Anti-DNA 17 <200 IU/ml negative
Anti-NMDA antibodies Negative Negative
Glutamate receptor IgG
antibodies
Not detectable Not detectable
Very long chain fatty
acids
Unremarkable -
Biotinidase 5.80 4.20–12.80 nM/minute/ml
Lactic acid 1.54 0.50–2.20 mmol/L
Newborn screening Unremarkable -
Cerebrospinal fluid
Glucose 3.7 3.30–4.40 mmol/L
Protein 0.44 0.15–0.40 g/L
RBC 11 Not significant
WBC <1 Not significant
Lactic acid 1.2 ≤2.20
Brucella (IgM, IgG) <10 Unremarkable
Measles (IgM, IgG) Negative -
Cytomegalovirus (PCR) Negative -
HSV (PCR) Not detected -
Anti-NMDA antibodies Negative -
Mycoplasma antibody Negative -
Culture and sensitivity Negative -
ALT alanine aminotransferase, AST aspartate aminotransferase, CK creatine kinase,
CO2 carbon dioxide, C3 complement component 3, C4 complement component 4,
DNA deoxyribonucleic acid, EBV Epstein–Barr virus, ESR erythrocyte sedimentation
rate, FT4 free thyroxine, GTP glutamyl transpeptidase, HSV herpes simplex virus, IgG
immunoglobulin G, IgM immunoglobulin M, NMDA N-methyl-D-aspartate, PCR
polymerase chain reaction, RBC red blood cells, TP total protein,
TSH thyroid-stimulating hormone,WBC white blood cells
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(ADOS). A diagnosis of ADHD (inattentive subtype) was
also made on the basis of parental history, academic
reports, and Conners Questionnaire; psychostimulant
medication was not considered to have been beneficial
in treating his ADHD symptoms.
Discussion
Our patient presented with dry scaly skin and pro-
nounced behavioral and neurological symptoms that in-
cluded: psychotic features, disorganized behavior, ADHD
(inattentive subtype), ASD, and a learning disability. His
EEG showed epileptiform discharges. Pharmacological
treatments to control the psychotic symptoms and epi-
lepsy were relatively effective. Genetic and biochemical
analysis confirmed the diagnosis of XLI.
It is feasible that the mutation encompassing the STS
gene and some, if not all, of the behavioral and neuro-
logical features seen in our patient are causally related.
The limited clinical literature documents several cases of
children in which XLI is comorbid with epilepsy/EEG
abnormalities, mental retardation, and ADHD or an
autism-related condition (particularly in the case of large
chromosomal deletions) [8, 20, 21], while animal studies
have emphasized a link between Sts deficiency and cog-
nitive and behavioral phenotypes associated with devel-
opmental disorders [11–13].
To the best of our knowledge, this is the first report of
psychosis consistent with a diagnosis of early-onset
schizophrenia in a child with confirmed XLI. Given the
comparative rarity of both XLI and psychosis in the gen-
eral population, our observations, together with previous
literature reporting paranoid schizophrenia in two fe-
males with deletions spanning STS [22] and implicating
STS deficiency in postpartum psychosis [23, 24], suggest
that, in addition to influencing risk of developmental
disorders, STS deficiency may also predispose to risk of
psychotic illness; this notion is consistent with the latest
genome-wide genetic screens which show that individual
polymorphisms or mutations may act as risk factors in
multiple developmental and affective conditions [25].
Our patient’s behavioral and neurological presentation
could feasibly be modulated by other genetic or environ-
mental factors segregating within his family; this idea is
supported by the strong family history of learning dis-
ability and the communication deficits in our patient’s
eldest sister. In addition, autosomal runs of homozygos-
ity could theoretically have contributed toward our pa-
tient’s clinical presentation through revealing recessive
deleterious mutations of relevance to brain function
[26]; however, the fact that exome sequencing detected
no coding mutations of clinical significance within these
regions makes this explanation unlikely. Finally, it is pos-
sible that living with a congenital skin condition and/or
treatment for that condition, for example retinoids or
poorly specified traditional and herbal remedies, may in-
fluence psychological function. There is a case report of
a woman with ichthyosis vulgaris who presented with a
schizophrenia-like psychosis and EEG abnormalities
similar to our patient [27]; however, she also had a
strong family history of psychosis and learning disability.
Conclusions
This case and the previous limited literature highlight the
severe behavioral, psychiatric, and neurological symptoms
that may be comorbid with XLI. Clearly, given the preva-
lence of the condition (~1 in 3000 to 6000 men, equiva-
lent to over 1.2 million individuals worldwide [4]), there is
a need for the physical and psychological phenotypes asso-
ciated with it (including the prevalence of psychosis) to be
comprehensively described. Such an endeavor will allow
individuals such as our case to have their condition and
potential comorbidities recognized and treated at an early
stage, and to be monitored closely by appropriate multi-
disciplinary teams.
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